Glenmark Pharma gets USFDA nod for cholesterol-lowering drug
The approved product is a generic version of MSD International's Vytorin tablets.
By PTI | Updated:
BCCL
New Delhi: Glenmark Pharmaceuticals Friday said it has received final approval from the US health regulator for Ezetimibe and Simvastatin tablets, used for treating high levels of cholesterol in the blood.
The approved product is a generic version of MSD International's Vytorin tablets.
The approval has been granted by the the United States Food and Drug Administration (USFDA) for Ezetimibe and Simvastatin tablets in the strengths of 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg, and 10 mg/80 mg, the company said in a statement.
Citing IQVIA sales data, Glenmark said Vytorin tablets' market achieved annual sales of approximately USD 92.4 million for the 12-month period ended April 2019.
The company said its current portfolio consists of 157 products authorised for distribution in the US and 58 ANDAs pending approval with the USFDA.
Shares of Glenmark Pharma closed 1.24 per cent lower at Rs 442.80 apiece on BSE.
The approved product is a generic version of MSD International's Vytorin tablets.
The approval has been granted by the the United States Food and Drug Administration (USFDA) for Ezetimibe and Simvastatin tablets in the strengths of 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg, and 10 mg/80 mg, the company said in a statement.
Citing IQVIA sales data, Glenmark said Vytorin tablets' market achieved annual sales of approximately USD 92.4 million for the 12-month period ended April 2019.
The company said its current portfolio consists of 157 products authorised for distribution in the US and 58 ANDAs pending approval with the USFDA.
Shares of Glenmark Pharma closed 1.24 per cent lower at Rs 442.80 apiece on BSE.
ADVERTISEMENT
Too busy to trade in stocks? Invest in Mutual Funds with ET Money!
Bookmark or read stories offline -
Download ET Markets APP
Download ET Markets APP
ADVERTISEMENT
